Abstract
Background: Gestational trophoblastic disease comprises hydatidiform moles and a rare group of malignancies that derive from trophoblasts. Although there are typical morphological features that may distinguish hydatidiform moles from non-molar products of conception, such features are not always present, especially at early stages of pregnancy. Furthermore, mosaic/chimeric pregnancies and twin pregnancies make pathological diagnosis challenging while trophoblastic tumours can also pose diagnostic problems in terms of their gestational or non-gestational origin. Objectives: The aim of this study was to show that ancillary genetic testing can be used to aid diagnosis and clinical management of GTD. Methods: Each author identified cases where genetic testing, including short tandem repeat (STR) genotyping, ploidy analysis, next-generation sequencing, and immunostaining for p57, the product of the imprinted gene CDKN1C, facilitated accurate diagnosis and improved patient management. Representative cases were chosen to illustrate the value of ancillary genetic testing in different scenarios. Outcome: Genetic analysis of placental tissue can aid in determining the risk of developing gestational trophoblastic neoplasia, facilitating discrimination between low risk triploid (partial) and high risk androgenetic (complete) moles, discriminating between a hydatidiform mole twinned with a normal conceptus and a triploid conception and identification of androgenetic/biparental diploid mosaicism/chimerism. STR genotyping of placental tissue and targeted gene sequencing of patients can identify women with an inherited predisposition to recurrent molar pregnancies. Genotyping can distinguish gestational from non-gestational trophoblastic tumours using tissue or circulating tumour DNA and can also identify the causative pregnancy which is the key prognostic factor for placental site and epithelioid trophoblastic tumours. Conclusions and Outlook: STR genotyping and p57 immunostaining have been invaluable to the management of gestational trophoblastic disease in many situations. The use of next-generation sequencing and of liquid biopsies is opening up new pathways for GTD diagnostics. Development of these techniques has the potential to identify novel biomarkers of GTD and further refine diagnosis.
References
1.
Savage PM, Sita-Lumsden A, Dickson S, Iyer R, Everard J, Coleman R, et al. The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. J Obstet Gynaecol. 2013 May;33(4):406–11.
2.
Kaur B. Pathology of gestational trophoblastic disease (GTD). Best Pract Res Clin Obstet Gynaecol. 2021 Mar;74:3–28.
3.
Ronnett BM. Hydatidiform moles: ancillary techniques to refine diagnosis. Arch Pathol Lab Med. 2018;142(12):1485–502.
4.
Fisher RA, Maher GJ. Genetics of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol. 2021 Feb;74:29–41.
5.
Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa C, et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24(Suppl 6):vi39–50.
6.
Buza N, Hui P. Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine. Mod Pathol. 2021 Sep;34(9):1658–72.
7.
Fisher RA, Kaur B. Molecular genotyping in the diagnosis of trophoblastic tumours. Diagn Histopathol. 2019 Feb;25(2):66–76.
8.
Usui H. Auxiliary and experimental diagnostic techniques for hydatidiform moles. J Obstet Gynaecol Res. 2022 Sep 13;48(12):3077–86. jog.15422.
9.
Niemann I, Vejerslev LO, Frøding L, Blaakær J, Maroun LL, Hansen ES, et al. Gestational trophoblastic diseases: clinical guidelines for diagnosis, treatment, follow-up, and counselling. Dan Med J. 2015 Nov;62(11):A5082.
10.
Hancock BW, Nazir K, Everard JE. Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome. J Reprod Med. 2006 Oct;51(10):764–6.
11.
Seckl MJ, Fisher RA, Salerno G, Rees H, Paradinas FJ, Foskett M, et al. Choriocarcinoma and partial hydatidiform moles. Lancet. 2000 Jul 1;356(9223):36–9.
12.
Cheung ANY, Khoo US, Lai CYL, Chan KYK, Xue WC, Cheng DKL, et al. Metastatic trophoblastic disease after an initial diagnosis of partial hydatidiform mole: genotyping and chromosome in situ hybridization analysis. Cancer. 2004 Apr 1;100(7):1411–7.
13.
Scholz NB, Bolund L, Nyegaard M, Faaborg L, Jørgensen MW, Lund H, et al. Triploidy – observations in 154 diandric cases. PLoS One. 2015 Nov 12. 10(11):e0142545.
14.
Lok C, van Trommel N, Massuger L, Golfier F, Seckl M; Clinical Working Party of the EOTTD, et al. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. Eur J Cancer. 2020 May;130:228–40.
15.
Imafuku H, Miyahara Y, Ebina Y, Yamada H. Ultrasound and MRI findings of twin pregnancies with complete hydatidiform mole and coexisting normal fetus: two case reports. Kobe J Med Sci. 2018 May 28;64(1):E1–5.
16.
Niemann I, Bolund L, Sunde L. Twin pregnancies with diploid hydatidiform mole and co-existing normal fetus may originate from one oocyte. Hum Reprod. 2008 Jun 20;23(9):2031–5.
17.
Xing D, Adams E, Zou YS, Morsberger L, Scanga LR, Gao FF, et al. Twin/multiple gestations with a hydatidiform mole: clinicopathologic analysis of 21 cases with emphasis on molecular genotyping and parental contribution. Am J Surg Pathol. 2022 Sep;46(9):1180–95.
18.
Slim R, Fisher R, Milhavet F, Hemida R, Rojas S, Rittore C, et al. Biallelic NLRP7 variants in patients with recurrent hydatidiform mole: a review and expert consensus. Hum Mutat. 2022 Jul 23;43(12):1732–44. humu.24439
19.
Fisher RA, Lavery SA, Carby A, Abu-Hayyeh S, Swingler R, Sebire NJ, et al. What a difference an egg makes. Lancet. 2011 Dec 3;378(9807):1974.
20.
Akoury E, Gupta N, Bagga R, Brown S, Déry C, Kabra M, et al. Live births in women with recurrent hydatidiform mole and two NLRP7 mutations. Reprod Biomed Online. 2015 Jul;31(1):120–4.
21.
Eagles N, Sebire NJ, Short D, Savage PM, Seckl MJ, Fisher RA. Risk of recurrent molar pregnancies following complete and partial hydatidiform moles. Hum Reprod. 2015 Sep;30(9):2055–63.
22.
Murdoch S, Djuric U, Mazhar B, Seoud M, Khan R, Kuick R, et al. Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans. Nat Genet. 2006 Mar;38(3):300–2.
23.
Parry DA, Logan CV, Hayward BE, Shires M, Landolsi H, Diggle C, et al. Mutations causing familial biparental hydatidiform mole implicate c6orf221 as a possible regulator of genomic imprinting in the human oocyte. Am J Hum Genet. 2011 Sep 9;89(3):451–8.
24.
Demond H, Anvar Z, Jahromi BN, Sparago A, Verma A, Davari M, et al. A KHDC3L mutation resulting in recurrent hydatidiform mole causes genome-wide DNA methylation loss in oocytes and persistent imprinting defects post-fertilisation. Genome Med. 2019;11(1):84.
25.
Sanchez-Delgado M, Martin-Trujillo A, Tayama C, Vidal E, Esteller M, Iglesias-Platas I, et al. Absence of maternal methylation in biparental hydatidiform moles from women with NLRP7 maternal-effect mutations reveals widespread placenta-specific imprinting. PLoS Genet. 2015 Nov;11(11):e1005644.
26.
Nguyen NMP, Ge ZJ, Reddy R, Fahiminiya S, Sauthier P, Bagga R, et al. Causative mutations and mechanism of androgenetic hydatidiform moles. Am J Hum Genet. 2018 Nov;103(5):740–51.
27.
Ogilvie CM, Renwick PJ, Khalaf Y, Braude PR. First use of preimplantation genotyping in prevention of recurrent diandric complete hydatidiform mole. Reprod Biomed Online. 2009 Aug;19(2):224–7.
28.
Cheung AN, Zhang HJ, Xue WC, Siu MK. Pathogenesis of choriocarcinoma: clinical, genetic and stem cell perspectives. Future Oncol. 2009 Mar;5(2):217–31.
29.
Hoffner L, Surti U. The genetics of gestational trophoblastic disease: a rare complication of pregnancy. Cancer Genet. 2012 Mar;205(3):63–77.
30.
Schmid P, Nagai Y, Agarwal R, Hancock B, Savage PM, Sebire NJ, et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet. 2009 Jul;374(9683):48–55.
31.
Froeling FEM, Ramaswami R, Papanastasopoulos P, Kaur B, Sebire NJ, Short D, et al. Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours. Br J Cancer. 2019 Mar;120(6):587–94.
32.
Shahib N, Martaadisoebrata D, Kondo H, Zhou Y, Shinkai N, Nishimura C, et al. Genetic origin of malignant trophoblastic neoplasms analyzed by sequence tag site polymorphic markers. Gynecol Oncol. 2001 May;81(2):247–53.
33.
Fisher RA, Savage PM, MacDermott C, Hook J, Sebire NJ, Lindsay I, et al. The impact of molecular genetic diagnosis on the management of women with hCG-producing malignancies. Gynecol Oncol. 2007 Dec;107(3):413–9.
34.
Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynecol Obstet. 2021 Oct;155(Suppl 1):86–93.
35.
Frijstein MM, Lok CAR, van Trommel NE, ten Kate-Booij MJ, Massuger LFAG, van Werkhoven E, et al. Management and prognostic factors of epithelioid trophoblastic tumors: results from the international society for the study of trophoblastic diseases database. Gynecol Oncol. 2019;152(2):361–7.
36.
Openshaw MR, Harvey RA, Sebire NJ, Kaur B, Sarwar N, Seckl MJ, et al. Circulating cell free DNA in the diagnosis of trophoblastic tumors. EBioMedicine. 2016 Feb;4:146–52.
37.
Maher GJ, Fisher RA, Kaur B, Aguiar X, Aravind P, Cedeno N, et al. Sensitive screening of single nucleotide polymorphisms in cell free DNA for diagnosis of gestational tumours. NPJ Genom Med. 2022 Dec;7(1):26.
38.
Castrillon DH, Sun D, Weremowicz S, Fisher RA, Crum CP, Genest DR. Discrimination of complete hydatidiform mole from its mimics by immunohistochemistry of the paternally imprinted gene product p57KIP2. Am J Surg Pathol. 2001 Oct;25(10):1225–30.
39.
Chilosi M, Piazzola E, Lestani M, Benedetti A, Guasparri I, Granchelli G, et al. Differential expression of p57kip2, a maternally imprinted cdk inhibitor, in normal human placenta and gestational trophoblastic disease. Lab Invest. 1998 Mar;78(3):269–76.
40.
Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem. 1983 Nov;31(11):1333–5.
41.
Usui H, Sato A, Shozu M. Parental contribution to trisomy in heterozygous androgenetic complete moles. Sci Rep. 2020 Dec;10(1):17137.
42.
Gaillot-Durand L, Patrier S, Aziza J, Devisme L, Riera AC, Marcorelles P, et al. p57-discordant villi in hydropic products of conception: a clinicopathological study of 70 cases. Hum Pathol. 2020 May;101:18–30.
43.
Hoffner L, Dunn J, Esposito N, Macpherson T, Surti U. P57KIP2 immunostaining and molecular cytogenetics: combined approach aids in diagnosis of morphologically challenging cases with molar phenotype and in detecting androgenetic cell lines in mosaic/chimeric conceptions. Hum Pathol. 2008 Jan;39(1):63–72.
44.
Hodgson A, Dube V, Strickland S, Kolomietz E, Noor A, Akbari A, et al. Androgenetic/biparental mosaic/chimeric conceptions with a molar component: a diagnostic and clinical challenge. Int J Gynecol Pathol. 2020 Oct 16;40(5):510–7.
45.
Murphy KM, Carrick K, Gwin K, Rogers V, Koduru P, Ronnett BM, et al. Rare complete hydatidiform mole with p57 expression in villous mesenchyme: case report and review of discordant p57 expression in hydatidiform moles. Int J Gynecol Pathol. 2022 Jan 1;41(1):45–50.
46.
Sunde L, Niemann I, Hansen ES, Hindkjaer J, Degn B, Jensen UB, et al. Mosaics and moles. Eur J Hum Genet. 2011 Oct;19(10):1026–31.
47.
Lewis GH, DeScipio C, Murphy KM, Haley L, Beierl K, Mosier S, et al. Characterization of androgenetic/biparental mosaic/chimeric conceptions, including those with a molar component: morphology, p57 immnohistochemistry, molecular genotyping, and risk of persistent gestational trophoblastic disease. Int J Gynecol Pathol. 2013 Mar;32(2):199–214.
48.
Buza N, McGregor SM, Barroilhet L, Zheng X, Hui P. Paternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform moles. Mod Pathol. 2019;32(8):1180–8.
49.
Fisher RA, Nucci MR, Thaker HM, Weremowicz S, Genest DR, Castrillon DH. Complete hydatidiform mole retaining a chromosome 11 of maternal origin: molecular genetic analysis of a case. Mod Pathol. 2004 Sep;17(9):1155–60.
50.
Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010 Aug;376(9742):717–29.
51.
Tidy J, Seckl MJ, Hancock BW. Management of gestational trophoblastic disease: green‐top guideline No. 38 – june 2020. BJOG. 2021 Feb;128(3):e1–27.
52.
Buza N. Gestational trophoblastic disease: contemporary diagnostic approach. Surg Pathol Clin. 2022 Jun;15(2):197–218.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
